Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes

被引:0
|
作者
Noh, Byeong-Joo [1 ]
Kim, Ji Hoon [2 ]
Eom, Dae-Woon [1 ]
机构
[1] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Pathol, Kangnung, South Korea
[2] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Surg, Kangnung, South Korea
基金
新加坡国家研究基金会;
关键词
PD-L1; CD8; tumor microenvironment immune type; gastric carcinoma; EPSTEIN-BARR-VIRUS; DEATH-LIGAND; WORSE SURVIVAL; CANCER; IMMUNOSCORE; PREDICTOR; BURDEN;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Goals. We categorized gastric cancers into four types of tumor immune microenvironment based on PD-L1 expression and tumor-infiltrating lymphocytes (TILs) to analyze clinicopathologic characteristics and recommend an immunotherapy-targetable subgroup. Procedures. Formalin-fixed, paraffin-embedded tissue samples of randomly selected gastric adenocarcinoma (n=479) were obtained and arrayed using a tissue-arraying instrument. Immunohistochemical stains for PD-L1, PD-1, and CD8 were performed and evaluated in addition to microsatellite instability, EBV infection, and HER-2 analyses. Results. Tumor microenvironment immune type (TMIT) I (both PD-L1-positive tumor cells & CD8-high TILs) and type III (PD-L1-positive tumor cells & CD8-low TILs) showed the best and worse prognosis, respectively. PD-L1 expression was significantly associated with Epstein-Barr virus infection (p<0.001) and microsatellite instability status (p<0.001). PD-L1 immunoreactivity was positively correlated with TILs having CD8 or PD-1 overexpression. Conclusions. TMIT I subgroup showed more patent CD8/PD-L1/PD-1 signaling pathway compared to other types. Therefore, TMIT I subgroup is a good candidate to predict effective response rate for immune checkpoint blockers. Such stratification of gastric cancers into four types can be used to predict the prognosis of patients and determine the immunotherapy-targetable subgroup.
引用
收藏
页码:695 / 706
页数:12
相关论文
共 50 条
  • [41] PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients
    Ren, Min
    Dai, Bo
    Kong, Yun-Yi
    Lv, Jiao-Jie
    Cai, Xu
    HISTOPATHOLOGY, 2018, 73 (03) : 386 - 396
  • [42] Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer
    Fang, Wenfeng
    Chen, Ying
    Sheng, Jin
    Zhou, Ting
    Zhang, Yaxiong
    Zhan, Jianhua
    Liu, Lin
    Huang, Jiaxing
    Peng, Peijian
    Zhang, Li
    JOURNAL OF CANCER, 2017, 8 (09): : 1579 - 1585
  • [43] Clinicopathological and Prognostic Significance of MSI Status and PD-L1 Expression in Turkish Patients with Gastric Cancer
    Bahsi, Seyma
    Yildiz, Ibrahim
    Erdamar, Sibel
    Goksel, Suha
    Tozun, Nurdan
    Aytac, Erman
    Demir, Gokhan
    Er, Ozlem
    Baca, Bilgi
    Karahasanoglu, Tayfun
    Hamzaoglu, Ismail
    Ozer, Leyla
    Bozkurt, Mustafa
    Uras, Cihan
    Bayoglu, Ibrahim Vedat
    Dulgeroglu, Onur
    Ince, Umit
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2021, 31 (04): : 246 - 254
  • [44] PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance
    Lian, Jie
    Zhang, Guanjun
    Zhang, Yun
    Liu, Heng
    Zhang, Jiaojiao
    Nan, Pengfei
    Tian, Wei
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (10) : 1419 - 1427
  • [45] Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas
    Vimalathas, Gayaththri
    Kristensen, Bjarne Winther
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2022, 48 (01)
  • [46] Clinicopathological and prognostic significance of PD-L1 expression in colon adenocarcinoma tumor budding
    Bas, Yilmaz
    Yilmaz, Bayram
    Guney, Guven
    Sahin, Havva Hande Keser
    Ozcerezci, Tugba
    Rencber, Emin
    Kocak, Ozgur
    Helvaci, Kaan
    Sahiner, Ibrahim Tayfun
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 67
  • [47] Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors
    Grabowski, P.
    Joehrens, K.
    Arsenic, R.
    Kaemmerer, D.
    Hummel, M.
    Scheibenbogen, C.
    Busse, A.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 107 - 108
  • [48] PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
    Yagi, Taisuke
    Baba, Yoshifumi
    Ishimoto, Takatsugu
    Iwatsuki, Masaaki
    Miyamoto, Yuji
    Yoshida, Naoya
    Watanabe, Masayuki
    Baba, Hideo
    ANNALS OF SURGERY, 2019, 269 (03) : 471 - 478
  • [49] Effects of Neoadjuvant Chemotherapy on the Expression of PD-L1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues
    Sun, W.
    Ma, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1071 - S1071
  • [50] Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review
    Lehmer, Larisa
    Choi, Franchesca
    Kraus, Christina
    Shiu, Jessica
    de Feraudy, Sebastien
    Elsensohn, Ashley
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (05) : 321 - 330